SCHEMBL797558

SCHEMBL797558

Cn1cncc1N1CCc2ccc(C(F)(F)F)cc2C1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.41
HTR2C P28335 2/20 0.41
HTR2B P41595 1/20 0.41
PARP1 P09874 1/20 0.41
PARP10 Q53GL7 1/20 0.41
CYP11B2 P19099 5/20 0.40
CYP11B1 P15538 4/20 0.40
CYP19A1 P11511 1/20 0.36
NOTUM Q6P988 1/20 0.36
DRD2 P14416 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
BRD9 Q9H8M2 1/20 0.35
HRH3 Q9Y5N1 1/20 0.35
IDO1 P14902 3/20 0.35
TDO2 P48775 2/20 0.35
NR1H2 P55055 1/20 0.34
NR1H3 Q13133 1/20 0.34
ALOX5AP P20292 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL793449 0.77 PARP1 (0.42) HTR2AHTR2CHTR2BPARP1PARP10
SCHEMBL798106 0.76 DRD2 (0.52) HTR2AHTR2CHTR2BPARP1PARP10
SCHEMBL793346 0.76 CYP11B2 (0.61) HTR2AHTR2CHTR2BPARP1PARP10
SCHEMBL807791 0.76 CYP11B2 (0.45) HTR2AHTR2CHTR2BPARP1PARP10
SCHEMBL793423 0.75 PARP1 (0.43) HTR2AHTR2CHTR2BPARP1PARP10
SCHEMBL797906 0.75 PARP1 (0.41) HTR2AHTR2CHTR2BPARP1PARP10
SCHEMBL798056 0.73 CYP11B1 (0.47) HTR2AHTR2CHTR2BPARP1PARP10
SCHEMBL797817 0.73 CYP11B2 (0.39) HTR2AHTR2CHTR2BPARP1PARP10
SCHEMBL793796 0.72 CYP17A1 (0.58)
SCHEMBL807977 0.70 MAOA (0.41) HTR2AHTR2CHTR2BPARP1PARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2014-02-13 US claimed
EP-2627648-A1 17aHYDROXYLASE/C17,20-LYASE INHIBITORS Novartis AG (CH) 2013-08-21 EP claimed
WO-2012035078-A1 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2012-03-22 WO claimed
US-8946260-B2 17α-hydroxylase/C17,20-lyase inhibitors NOVARTIS AG (CH) 2015-02-03 US disclosed
US-8946260-B2 17α-hydroxylase/C17,20-lyase inhibitors NOVARTIS AG (CH) 2015-02-03 US disclosed
US-8946260-B2 17α-hydroxylase/C17,20-lyase inhibitors NOVARTIS AG (CH) 2015-02-03 US disclosed
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2014-02-13 US disclosed
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2014-02-13 US disclosed
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2014-02-13 US disclosed
EP-2627648-A1 17aHYDROXYLASE/C17,20-LYASE INHIBITORS Novartis AG (CH) 2013-08-21 EP disclosed
WO-2012035078-A1 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS NOVARTIS AG (CH) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140045872-A1 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS CYP17A1, CYP21A2, HSD17B1 HTR2A 3716/4885HTR2C 2446/4885HTR2B 3184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.